Diana Abdulganieva
@kazangmu.ru
Kazan State Medical University, department of hospital therapy
Scopus Publications
Scopus Publications
Silvio Danese, Remo Panaccione, Brian G Feagan, Anita Afzali, David T Rubin, Bruce E Sands, Walter Reinisch, Julián Panés, Aparna Sahoo, Natalie A Terry,et al.
Elsevier BV
E. L. Nasonov , V. I. Mazurov, A. M. Lila, T. V. Dubinina, I. Z. Gaydukova, S. A. Lapshina, A. A. Klimenko, D. V. Somov, S. A. Lukianov, D. M. Chudakov,et al.
Mediar Press
The aim – to evaluate the clinical effectiveness, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of seniprutug (BCD-180) in patients with radiographic active axial spondyloarthritis (r-axSpA, or ankylosing spondylitis).Subjects and methods. 260 patients with active r-axSpA and inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) were randomized into three groups: seniprutug (BCD-180) at doses of 5 mg/kg or 7 mg/kg, or placebo. BCD-180 was administered on weeks 0–12–36. Patients in the placebo group were switched to BCD-180 at a dose of 5 mg/kg at week 24 and continued therapy at week 36. The primary endpoint was the proportion of patients achieving 40% improvement by Assessment in Spondyloarthritis International Society scale (ASAS40) at week 24. Secondary endpoints were proportion achieving ASAS20/40, improvement of 5 out of 6 criteria of ASAS (ASAS5/6), ASAS partial remission, clinically important improvement in ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score with C-reactive protein) (ASDAS-CII) and major improvement in ASDAS-CRP (ASDAS-MI). The dynamics of the disease activity status according to ASDAS-CRP, the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Functional Index) indices, as well as the dynamics of laboratory markers (C-reactive protein anderythrocyte sedimentation rate (ESR)) were analyzed. Safety was assessed by the frequency and profile of adverse events (AEs) and adverse reactions (ARs).Results. The proportion of patients achieving ASAS40 at week 24 with seniprutug (BCD-180) at the dose of 7 mg/kg and 5 mg/kg was 51.4% and 40.8%, respectively, compared with 24% in the placebo group (p=0.0012 and p=0.0417, respectively). Analysis of secondary endpoints showed that in patients with r-axSpA, BCD-180 at both study doses was significantly superior to placebo at week 24 in the following measures: decrease in the proportion of subjects with very high disease activity (ASDAS-CRP>3.5) achieving ASDAS-CII, ASAS20, ASAS5/6. A statistically significant decrease in the ASDAS-CRP, BASDAI, BASFI indices, as well as the concentration of CRP and ESR were demonstrated. Tolerability of seniprutug therapy was assessed as acceptable. Infusion reactions were the most common observed adverse events, the vast majority of which were mild to moderate in severity according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events) and developed predominantly during the first administration. The proportion of patients with binding antibodies was 5.1%. However, no neutralizing antibodies were detected.Conclusion. Seniprutug (BCD-180) demonstrated superiority over placebo in clinical efficacy with a favorable safety profile and low immunogenicity as a treatment of r-axSpA.
A. Kh. Odintsova, D. R. Akberova, L. R. Sadykova, N. A. Cheremina, M. M. Minnullin, A. A. Kirshin, E. N. Gabitova, A. Yu. Khasanshina, and D. I. Abdulganieva
Russian Gastroenterolgocial Society
Aim: to present the difficulties of long-term management of a patient with liver cirrhosis in the outcome of overlap syndrome (autoimmune hepatitis and primary biliary cholangitis) who suffered from severe COVID-19 infection.Key points. The diagnosis of liver cirrhosis as an outcome of overlap syndrome (autoimmune hepatitis and primary biliary cholangitis) was established at the patient’s age of 33 years. At the age of 40, the patient became pregnant for the first time, the pregnancy proceeded well, and a cesarean section was performed at 36 weeks. At the age of 45, the patient suffered a severe new coronavirus infection, followed by decompensation of liver cirrhosis, which required liver transplantation 4 months after COVID-19, followed by a favorable postoperative course.Conclusion. This clinical case demonstrates the successful onset and outcome of pregnancy in a patient with liver cirrhosis in the outcome of overlap syndrome (autoimmune hepatitis and primary biliary cholangitis). The pronounced activity of the disease after severe new coronavirus infection required liver transplantation with successful outcome.
V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova,et al.
IMA Press, LLC
The article presents the results of the three-year use of netakimab (NTK) in patients with ankylosing spondylitis (AS) as part of the phase III BCD-085-5/ASTERA study.Objective: to evaluate the long-term efficacy and safety of NTK over a three-year period in patients with active AS.Material and methods. BCD-085-5/ASTERA – double-blind, multicenter, randomized phase III clinical trial that enrolled patients with active AS (BASDAI ≥4) and a back pain intensity ≥4 on a numeric rating scale with inefficacy or intolerance of non-steroidal anti-inflammatory drugs or biologic drugs. A total of 228 patients were randomized in a 1:1 ratio and assigned to either the NTK group or the placebo/NTK group. Starting at week 16, patients who did not achieve ASAS20 (20% improvement according to ASAS criteria) received NTK 120 mg once every 2 weeks in an open-label regimen. Patients who achieved ASAS20 response at week 52 in the NTK group and week 68 in the placebo/NTK group continued to receive NTK (120 mg every 2 weeks) until week 156 in the NTK group and until week 172 in the placebo/NTK group.Results and discussion. Over the course of three years of NTK use, most patients experienced a sustained decline in AS activity (according to ASDAS-CRP, BASDAI) with sustained response (ASAS20/40, ASAS5/6) to therapy. Most adverse events reported were mild to moderate. 36.7% of patients had adverse events, which were mainly laboratory abnormalities, blood and lymphatic system abnormalities and infectious complications.Conclusion. The clinical effect of NTK was maintained in most patients with AS over a three-year period, with no significant loss of response. NTK was well tolerated and the safety profile remained favorable.
V.N. Mukhamadieva, , N.G. Shamsutdinova, R.Z. Abdrakipov, R.G. Mukhina, D.I. Abdulganieva, , , , ,et al.
LLC Russian Medical Journal
Aim: to study the incidence and duration of postcovid manifestations in patients with rheumatic diseases (RD), as well as the RD course patterns in the postcovid period. Patients and Methods: 271 patients (mean age 56 [46; 65] years) were included in the study: with a diagnosis of rheumatoid arthritis (RA) — 186 (68.6%) patients, with ankylosing spondylitis (SpA) — 46 (16.9%), with psoriatic arthritis — 38 (14%) patients who had previously suffered COVID-19. The presence of postcovid syndrome (PCS) was determined 3, 6, 9 or 12 months after acute COVID-19. An in-depth medical check- up questionnaire for citizens who have experienced COVID-19 was used to identify the clinical symptoms of PCS. The article presents the results of the following scales: the Hospital Anxiety and Depression Scale (HADS) was used to identify and evaluate the severity of depression and anxiety, the Hamilton Depression Rating Scale (HAM-D) — to evaluate depression, the Asthenic State Scale (ASS) — to diagnose asthenic condition, and the Mini Mental State Examination (MMSE) — to study the severity of cognitive disorder. RD course progression was assessed 3, 6, 9 and 12 months after the experienced COVID-19. Results: 75.3% of patients with RD had complaints characteristic of PCS, which could persist up to 12 months after undergoing COVID-19. 3 months after the COVID-19, during case follow-up and filling out the in-depth medical examination questionnaire, it was noticed that patients most commonly complained of increased joint pain (80.2% of patients), dyspnea, and reduced exercise tolerance (50.6% of patients). The second most common complaint was asthenovegetative manifestations. Given the analyze of RD activity in patients before, during and after the COVID-19 after 3, 6, 9 and 12 months, it was found that the maximum number of patients with RD exacerbation was 3 months after the COVID-19. It was also found that moderate and severe RD activity before COVID-19 had a direct effect on the incidence of increased joint pain 3 and 6 months after COVID-19. Patients with RD were significantly more likely to complain of reduced exercise tolerance, fatigue and muscle pain 3 and 6 months after COVID-19 versus patients with SpA. Anxiety-depressive disorders, cognitive impairments, and asthenic manifestations in the setting of PCS were registered more commonly in female patients for 6 months after undergoing COVID-19 than in male patients. Conclusion: complaints characteristic of PCS were revealed in most of the patients with RD, persisting up to a year after the COVID-19: arthralgia and asthenic manifestations (fatigue, faintness) were most common in the respondents. Moderate and severe RD activity before the COVID-19 caused increased joint pain 3 and 6 months after the recovery from COVID-19. 3 months after the experienced COVID-19, patients with RD had more complaints characteristic of PCS and an increase RD activity itself. The gender patterns during the PCS course in patients with RD were also revealed. KEYWORDS: new coronavirus infection, rheumatic diseases, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, postcovid syndrome, in-depth health check-up, musculoskeletal manifestations, anxiety, depression, cognitive impairment, asthenia. FOR CITATION: Mukhamadieva V.N., Shamsutdinova N.G., Abdrakipov R.Z., Mukhina R.G., Abdulganieva D.I. Postcovid syndrome in patients with rheumatic diseases. Russian Medical Inquiry. 2023;7(7):452–459 (in Russ.). DOI: 10.32364/2587-6821-2023-7-7-8.
T. V. Dubinina, A. B. Demina, E. M. Agafonova, Sh. F. Erdes, V. I. Mazurov, I. Z. Gaydukova, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan,et al.
IMA Press, LLC
The article contains the data obtained during the 156-week follow-up of patients with ankylosing spondylitis (AS) in the ASTERA phase III study.Objective: to evaluate the effect impact of netakimab (NTK) on quality of life (QoL), back pain and work capacity in patients with active AS.Material and methods. The study enrolled 228 patients with active AS who were randomized 1:1 to receive NTK 120 mg or placebo. At week 52, patients in Group 1 (NTK) who achieved ASAS20 continued therapy (NTK at a dose of 120 mg once every 2 weeks) until week 156. Patients in Group 2 (placebo/NTK) received the study drug at a dose of 120 mg subcutaneously every 2 weeks from week 20 until week 68, after which the efficacy of therapy was determined (by achieving an ASAS20 response). Patients who achieved ASAS20 received treatment (NTK at a dose of 120 mg once every 2 weeks) until week 172.Results and discussion. Under NTK therapy, a significant improvement in QoL was observed in the assessment of the physical and psychological components of the SF-36 questionnaire, which was maintained during the three years of therapy: increase in indicator by 12.68±9.92; 13.27±10.14; 12.92±10.03; 14.10±10.35; 14.76±9.77 and 6.10±11.59; 5.50±11.82; 6.32±11.01; 5.87±11.45; 5.25±11.98 points at week 52, 76, 104, 128 and 156, respectively. During the extended therapy period, a reduction in the proportion of working hours missed for health reasons, an improvement in work capacity and work efficiency and an increase in daily activity were observed. Back pain (BASDAI question 2) and nocturnal back pain decreased steadily during the entire follow-up period compared to the screening values.Conclusion. NTK is an effective therapy for active AS that improves QoL scores, significantly reduces pain intensity and improves work productivity.
D. D. Mukhametova, E. N. Belousova, Z. I. Fashieva, M. G. Nazarova, M. V. Knyazeva, and D. I. Abdulganieva
LLC Global Media Technology
The paper presents the results of an assessment cognitive function and ammonium levels in individuals who have had a novel coronavirus infection (COVID-19). The study included 60 people: 41 - confirmed COVID-19 during last 3 months and 19 - the control group. There have been performed clinical examination, psychometric test - connect-the-numbers test (CNT) and Mini-Mental State Examination (MMSE). Blood ammonium level has been determined. Post-COVID-19 syndrome (PCS) was diagnosed in 70.7% of patients, which was manifested by complaints of memory loss, weakness and anxiety. In patients who underwent COVID-19, cognitive impairment was detected on the MMSE scale in 27 people (45%), and the changes were more pronounced in the group with PCS. In the post-COVID group, 66% of the subjects had an increase CNT result. The cognitive impairment according to the MMSE correlated with the CNT results. Hyperammonemia was found in 54% of COVID-19 survivors, with higher values observed in the PCS group. No correlation was found between hyperammonemia and cognitive impairment.
T. Yu. Nuriahmetova, I. Kh. Valeeva, Y. O. Shevnina, A. V. Petrov, N. A. Cheremina, E. V. Sukhorukova, A. G. Vasiliev, and D. I. Abdulganieva
IMA Press, LLC
In clinical practice, differences in the efficacy of tumor necrosis factor-α inhibitors (iTNF-α) have been observed in different diseases.Objective: to evaluate the efficacy of iTNF-α in patients with immune-mediated diseases and its relation to the immunogenicity of these drugs.Material and methods. The study included 70 patients with rheumatic diseases (RD) and 53 with inflammatory bowel disease (IBD) treated with infliximab (IFN), adalimumab, or certolizumab pegol (CZP). Disease activity and response to therapy were evaluated, as well as measurement of the minimal residual concentration of iTNF-α and the level of anti-drug antibodies.Results and discussion. Therapy efficacy was maintained in 60 (85.7%) patients with RD and 35 (66.0%) with IBD (odds ratio, OR 1.3; p=0.01). Event-free survival of therapy was observed more frequently in RD and was longer than in IBD (p<0.01). The incidence of treatment failure was 3.13 times higher in IBD than in RD (p<0.01). In contrast to IBD, low TNF-α levels were more common in RD patients who did not respond to treatment than in those who did (80% and 40%, respectively; OR 6.0; p<0.05). Anti-TNF-α antibodies were detected in 75% of patients with ineffective treatment with INF and CZP in the RD group and in 14.3% in the IBD group (OR 0.06; p<0.05).Conclusion. In patients with RD, the effect of iTNF-α lasted more frequently and longer than in patients with IBD. In ankylosing spondylitis and rheumatoid arthritis, the ineffectiveness of iTNF-α was associated with the formation of anti-drug antibodies or their low concentration in most cases, but in IBD only in half of the cases.
E. L. Nasonov, V. N. Amirjanova, Y. A. Olyunin, Y. V. Muravyev, A. A. Baranov, E. V. Zonova, E. N. Otteva, A. I. Zagrebneva, D. I. Abdulganieva, and P. I. Pchelnikova
Mediar Press
Rheumatoid arthritis (RA) is the most frequent immunoinflammatory (autoimmune) rheumatic disease characterized by chronic erosive arthritis and systemic damage to internal organs. The data obtained in the course of basic research on deciphering the mechanisms of action of methotrexate (MT) and the materials of numerous randomized placebocontrolled trials, observational studies and national registries have strengthened the position of MT as the “gold standard” of RA pharmacotherapy and a key component of the “Treatment to Target” strategy. This was the basis for the development of new recommendations of the Association of Rheumatologists of Russia (ARR) concerning the use of MT in RA, according to which MT is considered as the drug of “choice” for induction and maintenance of remission in patients with early and advanced RA, including those who need combination therapy of MT with glucocorticoids, standard Disease-Modifying Antirheumatic Drugs (DMARDs), biologics and targeted synthetic DMARDs. Special attention is paid to the safety of MT therapy and the impact of MT on comorbid pathology associated with cardiovascular complications and interstitial lung disease. Implementation of the ARR recommendations into clinical practice will reduce the risk of disability and improve life prognosis in patients with RA.
Yury A. Shelygin, Vladimir T. Ivashkin, Sergey I. Achkasov, Igor V. Reshetov, Igor V. Maev, Elena A. Belousova, Armen V. Vardanyan, Bella A. Nanaeva, Leila V. Adamyan, Oksana M. Drapkina,et al.
Russian Association of Coloproctology
<jats:p>.</jats:p>
Yu. A. Shelygin, S. I. Achkasov, I. V. Reshetov, I. V. Mayev, O. M. Drapkina, E. A. Belousova, A. V. Vardanyan, B. A. Nanaeva, D. I. Abdulganieva, L. V. Adamyan,et al.
Russian Association of Coloproctology
AIM: to establish the consensus on controversial issues of the surgery for Сrohn’s disease by Delphi method.METHODS: a cross-sectional study was conducted by the Delphi method. 62 experts voted intramural and anonymous (31.03.23). 5 statements from the current edition of clinical guidelines were selected for correction by working group and further voting [2]. Based on the practical experience of the working group and literature data, 3 new statements were created also. Statements that do not reach the required level of agreement (80% or more) will be subjected to Round 2 of the Delphi method.RESULTS: all experts took part in the anonymous voting. The panel of experts is represented by 8 different areas of practical medicine and the median of the professional experience of the respondents was 30 (12–49) years. Of the 8 statements submitted for voting, consensus (80% or more) was reached on 6 out of 8. 2 statements have been revised by working group for the distance 2nd round of the Delphi study. Consensus (more than 80%) was reached on both.CONCLUSION: a cross-sectional study by the Delphi method provided the opinions of a panel of experts on controversial issues in the surgical treatment of Crohn’s disease. Statements that reach consensus will be included by the working group in a new edition of clinical guidelines of Crohn’s disease.
S. A. Lapshina, A. R. Garaeva, Z. N. Gabdullina, E. V. Sukhorukova, and D. I. Abdulganieva
Remedium, Ltd.
Introduction. Biological disease modifying drugs (bDMARD) in the treatment of ankylosing spondylitis (AS) have shown good results with the achievement and long-term preservation of remission. There is a discussion about the withdrawal of drugs without loss of effect in order to reduce the economic burden, drug load, adverse events, the possibility of interrupting therapy during surgical treatment.Aim. To evaluate the potential for sustaining the therapeutic effect of netakimab (NTK) after its discontinuation in patients with AS who have achieved remission.Materials and methods. A cohort of 11 patients diagnosed with ankylosing spondylitis (AS) who had achieved remission was included in this study. The patients were closely observed for 52 weeks after discontinuing NTK treatment. AS exacerbations, pain intensity, disease activity scores (BASDAI, ASDAS), enthesitis evaluations (MASES), functional impairments (BASMI and BASFI), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels were documented, as well as radiographic and MRI assessments of the sacroiliac joints and spine were performed.Results. Out of the 11 patients, 5 (45.5%) experienced AS exacerbations within the 12-month observation period. Patients who developed flare-ups had higher baseline levels of BASDAI, ASDAS, BASMI, and CRP at the time of NTK discontinuation. They also had a longer disease duration and were older compared to patients without relapse (p < 0.05). The presence of flare-ups was significantly associated (p < 0.05) with a history of peripheral arthritis, previous treatment with IFN-alpha, and the number of comorbidities. By week 52 of the observation period, patients demonstrated a deterioration in both activity and functional limitations (p < 0.05). Elevated ASDAS-CRP levels were found to be correlated (p < 0.05) with higher radiographic stages of sacroiliitis, the presence of syndesmophytes, functional limitations based on BASMI at the time of drug discontinuation, and the absence of continuous NSAID use. Significant prolongation of remission was associated with a substantial decline in ASDAS-CRP under NTK treatment (rSp = 0.996; p < 0.05), especially among younger patients (rSp = 0.607; p < 0.05).Conclusions. Approximately half of the patients who discontinued NTK therapy after achieving clinical and laboratory remission were able to sustain it. Maintenance of remission for 1 year was more prevalent in younger patients with shorter duration of AS, achieving inactive disease status based on ASDAS-CRP, fewer functional limitations, absence of peripheral arthritis, and comorbidities. Nevertheless, regular patient monitoring is necessary to promptly identify disease recurrence.
D. R. Akberova, A. Kh. Odintcova, and D. I. Abdulganieva
Russian Gastroenterolgocial Society
Аim: to evaluate the state of small intestine permeability by the “double sugar test” in patients with overlap syndrome (autoimmune hepatitis / primary biliary cholangitis (AIH / PBC)).Materials and methods. Prospectively, 56 people were included in the study. Of these, 26 were diagnosed with AIH/PBC, 30 were in the control group. The diagnosis was made in accordance with the current recommendations. The average age of patients was 49.7 ± 13.8 years, healthy volunteers — 48.6 ± 9.2 years. The determination of the permeability of the small intestine was carried out by a “double sugar test” (the ratio of lactulose/mannitol in urine), using the method of high-performance liquid chromatography — mass spectrometry.Results. In patients with AIH/PBC, an increase in intestinal permeability was found — 0.20 [0.09; 0.30] (p < 0.001) compared with the control group 0.01 [0.01; 0.02]. We divided patients at the stage of liver damage. An increased small intestinal permeability was revealed: hepatitis stage — 0.19 [0.13; 0.30] (p < 0.001), liver cirrhosis stage — 0.18 [0.09; 0.30] (p < 0.05) compared with the control group. In the early stages of disease (1 month from the onset of the disease) had an increased lactulose/mannitol ratio — 0.13 [0.05; 0.26] (p < 0.001) compared to the control group. In the presence of portal hypertension (PH), small intestinal permeability was increased — 0.18 [0.09; 0.30] (p < 0.001) compared with the control group.Conclusions. An increase in small bowel permeability was found in patients with overlapping syndrome. All patients had increased intestinal permeability (regardless of the presence of extrahepatic manifestations).
O. M. Drapkina, L. B. Lazebnik, I. G. Bakulin, M. S. Zhuravleva, N. V. Bakulina, E. V. Skazyvaeva, S. I. Sitkin, M. I. Skalinskaya, O. I. Solovyeva, E. Yu. Eremina,et al.
LLC Global Media Technology
Clostridioides difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea, and an important cause of nosocomial infection. Since the publication of the National Guidelines (2016, 2017), new data have been accumulated on the genetic structure and pathogenic properties of the most common causative agent of severe forms of antibiotic- associated diarrhea, which has led to the reclassifi cation of the pathogen, formerly known as Clostridium diffi cile, to Clostridioides difficile. Laboratory algorithms have been developed to diagnose CDI and determine the toxigenicity of strains reliably. New data on the effectiveness of antibacterials have been published, monoclonal antibodies to toxin B (bezlotoxumab) have been introduced into clinical practice to prevent CDI recurrence, and fecal microbiota transplantation has been proposed. Over the past 5 years, many international guidelines on the management of adult patients with CDI have also been updated (USA, EU). In the last decade, including due to the COVID-19 pandemic, there has been an increase in CDI incidence. Considering therelevance of CDI, new data on the pathogen, and domestic features, the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientific Society of Russia, and the North-West Society of Gastroenterologists and Hepatologists developed these clinical guidelines.
E. F. Iskhakova, E. V. Sukhorukova, M. Yu. Badeeva, E. V. Dyakova, S. A. Lapshina, T. V. Beketova, and D. I. Abdulganieva
Mediar Press
Patients with ANCA-associated vasculitis (AAV) cause extreme alertness during the coronavirus disease 2019 (COVID-19) pandemic, associated with many factors: the initial damage to the respiratory system (upper respiratory tract, lungs) and kidneys, immunosuppressive treatments, difficult prognosis of COVID-19 with the risk of AAV exacerbation. We present a clinical case of а moderate COVID-19 in a patient with granulomatosis with polyangiitis, who received anti-B cell therapy with rituximab (RTX) for a long time. Coronavirus pneumonia developed one year after RTX, while B-lymphocyte depletion persisted. In order to achieve an adequate antiviral immune response and prevent hyperinflammation, treatment was carried out with antiviral drugs, anticoagulants, convalescent plasma, human normal immunoglobulin, and interleukin-6 antagonist tocilizumab. Possible predictors of severe COVID-19 in patients with AAV are discussed.
Yu. A. Shelygin, V. T. Ivashkin, E. A. Belousova, I. V. Reshetov, I. V. Maev, S. I. Achkasov, D. I. Abdulganieva, O. A. Alekseeva, I. G. Bakulin, O. Yu. Barysheva,et al.
Russian Association of Coloproctology
<jats:p>.</jats:p>
Alsu N. Gainetdinova, Luisa N. Zalyalyutdinova, and Диана Ильдаровна Абдулганиева
ECO-Vector LLC
Background. The social significance of such inflammatory diseases as rheumatoid arthritis is growing all over the world, which determines the need to find new ways to optimize the ongoing standard therapy.
 Aim. Evaluation of the effect of combined use of thioctic (lipoic) acid with methotrexate in comparison with methotrexate and meloxicam therapy on the psycho-emotional state of patients with rheumatoid arthritis and hepatic steatosis.
 Material and methods. The study included 60 women diagnosed with rheumatoid arthritis and hepatic steatosis. By the beginning of the observation, patients divided into two groups were comparable according to all criteria for inclusion in the study. The first group took methotrexate and thioctic (lipoic) acid, the second group methotrexate and meloxicam daily for a month. The psycho-emotional state of the patients according to the Spielberger tests modified by Yu.L. Khanin and depression according to Beck were assessed. Determination of pro-inflammatory cytokines was carried out by enzyme immunoassay. The research results were subjected to statistical processing.
 Results. An intergroup analysis showed that the use of thioctic acid and methotrexate led to a significant decrease in the level of anxiety in patients, in contrast to women taking methotrexate and meloxicam (the level of reactive anxiety decreased by 2.7 times compared with baseline data; p=0.03). It is also important to note the revealed correlation between the degree of decrease in the level of tumor necrosis factor and the severity of anxiety 1 month after taking the cytostatic and the hepatoprotector (Kendal's Tay-b correlation coefficient, r=0.732, p=0.046).
 Conclusion. The inclusion of thioctic (lipoic) acid in the basic therapy with methotrexate in patients with rheumatoid arthritis and hepatic steatosis improves their psycho-emotional state in the form of a decrease in anxiety-depressive spectrum disorders, practically normalizing the level of pro-inflammatory tumor necrosis factor , the degree of reduction of which correlates with the degree of reduction in the level of anxiety.
E. A. Belousova, Yu. A. Shelygin, S. I. Achkasov, I. E. Khatkov, I. G. Bakulin, M. I. Skalinskaya, O. V. Knyazev, A. V. Kagramanova, T. V. Shkurko, B. A. Nanaeva,et al.
Russian Association of Coloproctology
The National Registry of Patients with Inflammatory Bowel Disease (IBD) in the Russian Federation was established to study the epidemiological and clinical characteristics of patients and evaluate the actual clinical practice of medical and surgical treatment.AIM: to analyze the data of patients with IBD in the Russian Federation including clinical and demographic characteristics, medical status of patients, the frequency of use of various classes of drugs and response to treatment, the survival rates of advanced therapy drugs and the reasons for their cancellation.METHODS: from May 2017 to August 2021, depersonalized data of 3827 adult patients with IBD (ulcerative colitis (UC) – 2358 pts, Crohn's disease (CD) - 1469 pts) from 80 regions of the Russian Federation were included in the registry, both with previously and newly diagnosed UCor CD, who are in inpatient or outpatient care.RESULTS: in our population, the ratio of UC: CD was 1.6:1. The distribution of patients by sex was the same. The average age of patients in the registry was 40.6±13.1 (13-83 years) for UC and 38.5±14.3 (15-75 years) for CD, the half of patients were in the age range of 21-40 years for both diseases. The average age of disease onset did not differ for UC and CD and was 35.3 year (12-75 years) and 31.2 year (14-72 years) respectively. The duration between the onset of symptoms and the establishment of a diagnosis was 13.2 months in UC, and statistically significantly longer in CD - 34.8 months (P<0.01). The proportion of smokers in CD patients was statistically significantly higher than in UC ones (14.6% versus 9.6%, respectively, P<0.001). The incidence of disability was also significantly higher in CD than in UC patients (41.7% vs. 29.8%, P<0.01). The diagnosis of mild UC was established in 36% of cases, moderate UC occurred in 48.9% of patients, severe UC in 14.2% of patients. For the first time, the frequency of acute severe UC (1%) was estimated. The majority of patients had total UC (56.8%), 33% had left-side colitis, and 9.4% had proctitis. CD was divided by localization into ileocolitis 55.9%, terminal ileitis 23.9%, colitis 20.2%, perianal lesions were noted in 32.5% of cases. The overall complication rate in CD was 46% (681 patients), of which the most common were strictures - 48% and fistulas- 25.1%.Frequencyof extra intestinal manifestations did not differ in UC and CD patients and was 20.1% (473 patients) and 24.5% (360 patients), respectively. Of these, musculoskeletal lesions were more common (41.6% in UC, 42% in CD), lesions of the skin, eyes, mucous membranes, liver, anemia were also noted. In the treatment of IBD, steroids were used most often (79.3% and 65% in UC and CD, respectively), followed by 5-ASA - 47% in UC, 32.4% in CD. Immunosuppressant’s in CD were prescribed significantly more often (28.4%) than in UC (11%) (p<0.05). Biologics were used in 20.6% of UC patients and in 30% of CD patients. The highest 2-year survival of advanced therapy was noted for ustekinumab in CD (96%), for tofacitinib in UC (89.3%), and for vedolizumab in both UC and CD (92.5% and 88.4% respectively). The survival rates of all TNF-α inhibitors were approximately the same and varied within 58.1-72.4% in UC and 60-70% in CD. The most common reasons for discontinuation of advanced treatment were lack of efficacy/loss of response in both UC and CD. The second common reason was achieving remission. Certolizumab pegol in CD was canceled for this reason most often- 22.7% of cases. A small number of patients discontinued treatment due to adverse events: for UC - 1 patient each on adalimumab, golimumab, and tofacitinib, and 7 patients on infliximab, for CD- 5 patients on infliximab and adalimumab (9.6% and 7.5%, respectively) and 2 patients (4.6%) on certolizumab. Unfortunately, the proportion of discontinuation for non-medical reasons was significant and varied from 7% to 50% for different drugs. In some patients, the reason for discontinuation of therapy remained unknown.CONCLUSION: The difficulties of differential, often untimely diagnosis of CD and UC, the predominance of complicated and severe forms against the background of an increase in morbidity and prevalence, and at the same time the lack of adequate statistical accounting of CD and UC, make it necessary to create a unified clinical register of patients with IBD. The register of IBD patients will provide a holistic picture of the IBD situation in the country, including optimizing the use of budget funds for the treatment of patients with CD and UC, ensuring their rational planning.
I. F. Fairushina, D. I. Abdulganieva, S. P. McKenna, and A. Сoffey
IMA Press, LLC
Psoriatic arthritis (PsA) is a chronic progressive disease from the pondyloarthritis group of diseases. In recent years, there has been a significant increase in the incidence of PsA and cases of its severe course, with significant influence on the quality of life (QoL) of patients and early disability. Psoriatic Arthritis Quality of Life Questionnaire (PsAQoL) is the first quality of life questionnaire designed specifically for PsA that has not been previously validated in Russia.Objective: to translate the original PsAQoL questionnaire into Russian and evaluate the psychometric properties of the Russian version.Material and methods. The original PsAQoL was translated into Russian using two translational panels. In all, 12 local residents were included in the translation stage of the study. The external and logical validity of the questionnaire was assessed. Further, Russian-speaking patients with an established diagnosis of PsA (n=10) tested the questionnaire. A separate cohort of patients with PsA (n=50) was enrolled in a postal test retest study on 2 occasions, 2 weeks apart. Clinical data and the Medical Outcomes Study-Short Form (SF-36) questionnaire were used to assess convergent validity.Results and discussion. The Russian version of PsAQoL was relevant, clear, and easy to complete (6.1 minutes on average). PsAQoL had high internal consistency (Cronbach's á=0.87) and excellent retest validity (r>0.85). PsAQoL scores correlated most strongly with the SF-36 General Health Scale (r=-0.68, p<0.01). PsAQoL score did not depend on sex and age (p>0.05). The PsAQoL could distinguish between groups of patients defined by self-reported general health status and self-reported severity of PsA.Conclusion. The Russian version of PsAQoL proved to be understandable and easy to complete, as well as a reliable and valid tool for assessing the quality of life of patients with PsA.
Evgenia Bodryagina, Alfiya Odintsova, Natalia Cheremina, Nataliya Blatt, Dilyara Akberova, and Diana Abdulganieva
Springer Science and Business Media LLC
Diana I. Abdulganieva, Dilyara D. Mukhametova, Ildariia K. Valeeva, N. Blatt, Oleg D. Zinkevich, Nellya A. Safina, Alfiya Kh. Odintsova, and Marina O. Korovina
Springer Science and Business Media LLC
Dilyara Akberova, Ivan A. Kiyasov, Diana Abdulganieva, and Alfiya Odintsova
Springer Science and Business Media LLC
Dilyara Akberova, Ivan A. Kiyasov, Diana Abdulganieva, and Alfiya Odintsova
Springer Science and Business Media LLC
L.M. Kupkenova, , N.G. Shamsutdinova, A.Kh. Odintsova, N.A. Cheremina, D.G. Iskhakova, D.I. Abdulganieva, , , ,et al.
LLC Russian Medical Journal
Aim: to assess the presence and course of postcovid syndrome in patients with inflammatory bowel diseases (IBD), as well as to study the IBD course in the postcovid period. Patients and Methods: 125 patients with Crohn’s disease (CD) and ulcerative colitis (UC) in the postcovid period were sequentially included in the study. Assessment of the postcovid syndrome was conducted 3, 6, 9 or 12 months after acute period of COVID-19. A questionnaire included in an in-depth medical check-up for citizens who have experienced COVID-19 was used to identify the clinical symptoms of postcovid syndrome. The article presents the results of the following scales: Hospital Anxiety and Depression Scale (HADS) — to identify and evaluate the severity of depression and anxiety, Hamilton Depression Rating Scale (HAM-D) — to evaluate depression, Asthenic State Scale (ASS) — to diagnose asthenic condition, Mini Mental State Examination (MMSE) — to study the severity of cognitive disorder. The nature of the IBD course and the change in therapy were also evaluated. Results: 81 (64.8%) patients were diagnosed with CD, and 44 (35.2%) — with UC. The mean age of patients was 41.8±14.5 years, of which 68 (54.4%) were male, 57 (45.6%) — female. When filling up the questionnaire of the in-depth medical check-up 3 months after COVID-19, 47.8% of patients most commonly noted fatigue, and/or muscle pain, and/or headaches, and/or dysautonomia, and/or cognitive disorder, while 34.7% of patients — dyspnea, reduced exercise tolerance and/or chronic cough, and joint pain. Thus, postcovid manifestations occurred in approx. 47.8% of patients with IBD. An increase of complaints frequency, characteristic of postcovid syndrome, was noted by the 6th month after COVID-19. By the 9th and 12th month, the frequency of complaints decreased. When analyzing complaints related to asthenia, cognitive disorder, anxiety and depression, there was a tendency to the maximum number of disorders 6 months after COVID-19. Studying the activity in patients with IBD before, during and after COVID-19 (after 3, 6, 9 or 12 months), it was noted that the largest number of patients with acute IBD was 6 months after COVID-19. Conclusions: 47% of patients with IBD had complaints characteristic of postcovid syndrome, which persisted up to 12 months after COVID-19. Asthenia was the most common. Several complaints were increasing by the 6th month. IBD exacerbation rate reached its maximum value also by the 6th month after COVID-19. KEYWORDS: inflammatory bowel diseases, ulcerative colitis, Crohn’s disease, new coronavirus infection, COVID-19, postcovid syndrome, anxiety, depression, cognitive disorder, asthenia. FOR CITATION: Kupkenova L.M., Shamsutdinova N.G., Odintsova A.Kh. et al. Postcovid syndrome in patients with inflammatory bowel diseases. Russian Medical Inquiry. 2022;6(5):227–231 (in Russ.). DOI: 10.32364/2587-6821-2022-6-5-227-231.